[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO992779D0 - OB-fusjonsproteinpreparater og fremgangsmÕte for fremstilling av slike - Google Patents

OB-fusjonsproteinpreparater og fremgangsmÕte for fremstilling av slike

Info

Publication number
NO992779D0
NO992779D0 NO992779A NO992779A NO992779D0 NO 992779 D0 NO992779 D0 NO 992779D0 NO 992779 A NO992779 A NO 992779A NO 992779 A NO992779 A NO 992779A NO 992779 D0 NO992779 D0 NO 992779D0
Authority
NO
Norway
Prior art keywords
preparation
methods
fusion protein
protein preparations
preparations
Prior art date
Application number
NO992779A
Other languages
English (en)
Other versions
NO324506B1 (no
NO992779L (no
Inventor
Michael Benjamin Mann
Randy Ira Hecht
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO992779D0 publication Critical patent/NO992779D0/no
Publication of NO992779L publication Critical patent/NO992779L/no
Publication of NO324506B1 publication Critical patent/NO324506B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
NO19992779A 1996-12-20 1999-06-08 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat. NO324506B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (3)

Publication Number Publication Date
NO992779D0 true NO992779D0 (no) 1999-06-08
NO992779L NO992779L (no) 1999-08-19
NO324506B1 NO324506B1 (no) 2007-11-05

Family

ID=25090296

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19992779A NO324506B1 (no) 1996-12-20 1999-06-08 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat.
NO20071415A NO325096B1 (no) 1996-12-20 2007-03-16 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20071415A NO325096B1 (no) 1996-12-20 2007-03-16 OB-fusjonsprotein, nukleinsyresekvens, vektor, vertscelle, fremgangsmate for fremstilling av proteinet, farmasoytisk preparat samt anvendelse av proteinet for fremstilling av et terapeutisk preparat.

Country Status (26)

Country Link
EP (2) EP1835030A1 (no)
JP (2) JP4175668B2 (no)
KR (1) KR100937550B1 (no)
CN (1) CN1195858C (no)
AR (2) AR009436A1 (no)
AT (1) ATE351910T1 (no)
AU (1) AU5606098A (no)
BG (1) BG64288B1 (no)
BR (1) BR9713755A (no)
CA (1) CA2275183A1 (no)
CZ (1) CZ298203B6 (no)
DE (1) DE69737266T2 (no)
DK (1) DK0954588T3 (no)
EA (2) EA004790B1 (no)
ES (1) ES2280083T3 (no)
HK (1) HK1021388A1 (no)
HU (1) HU227088B1 (no)
IL (1) IL130396A (no)
NO (2) NO324506B1 (no)
NZ (1) NZ514145A (no)
PL (1) PL194159B1 (no)
PT (1) PT954588E (no)
RS (1) RS49927B (no)
SK (1) SK287578B6 (no)
WO (1) WO1998028427A1 (no)
ZA (1) ZA9711239B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
CA2286098C (en) * 1997-04-17 2009-07-07 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
BRPI9914698B8 (pt) 1998-10-23 2021-05-25 Amgen Inc composto que se liga a um receptor mp1, e , composição farmacêutica.
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001081377A2 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
WO2003034996A2 (en) 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
CA2555894A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2624893C (en) 2005-10-21 2015-03-17 Erhard Kopetzki Method for the recombinant expression of a polypeptide
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
DK2764565T3 (da) 2011-10-05 2023-04-17 Oned Mat Inc Aktive siliciumnanostrukturmaterialer til lithiumionbatterier og fremgangsmåder, sammensætninger, komponenter og anordninger i forbindelser dermed
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
CZ9802013A3 (cs) * 1995-12-27 1998-09-16 Genentech, Inc. Deriváty OB proteinu, chimerní OB polypeptidy, prostředky pro léčbu obezity a dalších fyziologických stavů a způsob léčení těmito prostředky, kódující sekvence pro OB protein, expresní vektor nesoucí tuto sekvenci, buňky transformované tímto vektorem a způsob jejich kultivace, a způsob navození růstu buněk s pomocí OB proteinu

Also Published As

Publication number Publication date
CA2275183A1 (en) 1998-07-02
PT954588E (pt) 2007-03-30
DE69737266D1 (de) 2007-03-08
DE69737266T2 (de) 2007-11-08
CZ9902036A3 (cs) 2000-10-11
BR9713755A (pt) 2000-02-01
NO325096B1 (no) 2008-02-04
NZ514145A (en) 2003-08-29
NO20071415L (no) 1999-08-19
WO1998028427A1 (en) 1998-07-02
EA004790B1 (ru) 2004-08-26
HUP0000302A2 (hu) 2000-06-28
CZ298203B6 (cs) 2007-07-18
CN1195858C (zh) 2005-04-06
HK1021388A1 (en) 2000-06-09
PL334242A1 (en) 2000-02-14
EA199900575A1 (ru) 2000-02-28
NO324506B1 (no) 2007-11-05
KR20000069617A (ko) 2000-11-25
CN1246154A (zh) 2000-03-01
NO992779L (no) 1999-08-19
AR009436A1 (es) 2000-04-12
AR059907A2 (es) 2008-05-07
ATE351910T1 (de) 2007-02-15
EP1835030A1 (en) 2007-09-19
SK77499A3 (en) 2001-04-09
YU27999A (sh) 2000-10-30
AU5606098A (en) 1998-07-17
JP2001512417A (ja) 2001-08-21
SK287578B6 (sk) 2011-03-04
RS49927B (sr) 2008-09-29
HU227088B1 (en) 2010-06-28
EP0954588A1 (en) 1999-11-10
HUP0000302A3 (en) 2005-12-28
ZA9711239B (en) 1998-06-23
BG64288B1 (bg) 2004-08-31
EA200100216A1 (ru) 2001-08-27
EA004791B1 (ru) 2004-08-26
KR100937550B1 (ko) 2010-01-19
ES2280083T3 (es) 2007-09-01
BG103522A (en) 2000-03-31
JP4175668B2 (ja) 2008-11-05
IL130396A (en) 2011-09-27
EP0954588B1 (en) 2007-01-17
IL130396A0 (en) 2000-06-01
PL194159B1 (pl) 2007-05-31
DK0954588T3 (da) 2007-05-14
JP2008289487A (ja) 2008-12-04
JP4659068B2 (ja) 2011-03-30

Similar Documents

Publication Publication Date Title
NO992779D0 (no) OB-fusjonsproteinpreparater og fremgangsmÕte for fremstilling av slike
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
IS4879A (is) Efnablöndur dreifanlegra stórsameinda og aðferðirtil gerðar þeirra og notkunar
IS4496A (is) Úðablöndur úr peptíðum og próteinum
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
DK0850948T3 (da) Propiophenonderivater og fremgangsmåde til fremstilling deraf
AU4648697A (en) Methods and devices for preparing protein concentrates
NO971582L (no) Bearbeidet myseprotein og fremgangsmåte for fremstilling av dette
NO20015859D0 (no) A-<beta>peptidpreparater og fremgangsmåter for fremstilling av slike
DK0906029T3 (da) Isoflavonberiget sojaproteinprodukt og fremgangsmåde til fremstilling heraf
NO2009028I1 (no) Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
FI962844A0 (fi) T-soluantigeenireseptorin V-alueen proteiineja ja menetelmiä niiden valmistamiseksi
DE69528180D1 (de) Modifiziertes molkeprotein
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
DE59707298D1 (de) Desodorierende zubereitungen
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
NO971505D0 (no) Trofinin og trofininhjelperproteiner
NO960766D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
ATE186559T1 (de) Leukoindigo-präparationen in granulatform
NO974932L (no) Pesticidpreparater og fremgangsmåte for fremstilling derav
EE9900092A (et) PTX-tundlikud G-valgud, nende valmistamine ja kasutamine
NO985572D0 (no) Substituerte amidinobenzenderivater og medisinske preparater derav
SE9602287D0 (sv) Novel protein and methods for its use
ZA983159B (en) Protein and method for producing the proteins

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees